Gilead
Last updated Jun 16, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
1
Clinical Programs
0
Confidence Coverage
65%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Infectious Disease
- HIV
Highest priority development: FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Regulatory precedent
Why this matters: provides agency context on approval that may shape timing or evidence expectations for Gilead.
Competitive pressure: Low
Portfolio impact: Moderate
Evidence coverage: 65%
Active Signals
1
Investigate Priority
1
Opportunity Score
28
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- InvestigateJun 16, 2026Score 28Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinomaModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 28Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Gilead right now?
- Which regulatory precedents should Gilead monitor in Infectious Disease and HIV?
- Which pipeline programs should Gilead prioritize for competitive review?
- What signals require immediate investigation for Gilead?
- Summarize the strategic implications of recent developments for Gilead.
- Where is the greatest uncertainty in Gilead's competitive positioning?